Medical Watch Disease & Treatment News

Personalized mRNA Melanoma Vaccine Reports Positive Phase 3 Outcomes

Personalized mRNA Melanoma Vaccine Reports Positive Phase 3 Outcomes

A personalized mRNA vaccine combined with pembrolizumab was reported to improve recurrence-free and distant metastasis-free survival in high-risk melanoma. Coverage lacks underlying figures and full trial results; longer follow-up and safety data are needed, and FDA approval is only anticipated for 2027.

Sources (2)
Updated Nov 20, 2026
Personalized mRNA Melanoma Vaccine Reports Positive Phase 3 Outcomes - Medical Watch Disease & Treatment News | NBot | nbot.ai